<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958321</url>
  </required_header>
  <id_info>
    <org_study_id>CTRIAL-IE (ICORG)06-35</org_study_id>
    <secondary_id>CTRIAL-IE (ICORG) 06-35</secondary_id>
    <secondary_id>EU-20925</secondary_id>
    <nct_id>NCT00958321</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35</brief_title>
  <official_title>Prospective Evaluation of PET-CT Scan in Patients With Non-operable or Non-resectable NSCLC Treated by Radical 3-Dimensional Conformal Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as positron emission tomography and computed&#xD;
      tomography, may help learn the extent of disease and allow doctors to plan 3-dimensional&#xD;
      conformal radiation therapy.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of positron emission tomography and&#xD;
      computed tomography and to see how well it works in planning treatment for patients&#xD;
      undergoing 3-dimensional conformal radiation therapy for non-small cell lung cancer that&#xD;
      cannot be removed by surgery.&#xD;
&#xD;
      This is a clinical study, as the patient will be treated using the PET-CT-GTV: - The pilot&#xD;
      study is investigating the technological feasibility - The Phase II study will be a 2-stage&#xD;
      Phase II study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot Study- Primary Objectives:&#xD;
&#xD;
        -  Prospective evaluation of the technical feasibility of integrating PET-CT fusion in St&#xD;
           Luke's Hospital&#xD;
&#xD;
        -  Rate of PET-CT Scan based treatment delivery&#xD;
&#xD;
      Pilot Study- Secondary Objectives:&#xD;
&#xD;
      -Comparison of GTV, PTV and OAR DVHs between conventional 3-DCRT plan and PET-CT based 3-DCRT&#xD;
      plan.&#xD;
&#xD;
      Phase II Study- Primary Objective:&#xD;
&#xD;
      -The safety of PET-CT scan based radiotherapy, with regard to loco-regional disease control.&#xD;
&#xD;
      Phase II Study- Secondary Objectives:&#xD;
&#xD;
      -Comparison of GTV, PTV and OAR DVHs between conventional 3-DCRT plan and PET-CT based 3-DCRT&#xD;
      plan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low levels of recruitment&#xD;
  </why_stopped>
  <start_date>March 2007</start_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of successful delivery of PET-CT scan based 3-D conformal radiotherapy (Pilot)</measure>
    <time_frame>2016</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of loco-regional recurrence outside the PET-CT planning target volume (PTV) but within conventional 3-D PTV (Phase II)</measure>
    <time_frame>2016</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute and long-term radiation-induced toxicity</measure>
    <time_frame>2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of dose delivery to organs at risk, according to planning method</measure>
    <time_frame>2016</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>3-DCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <arm_group_label>3-DCRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <arm_group_label>3-DCRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <arm_group_label>3-DCRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy treatment planning/simulation</intervention_name>
    <arm_group_label>3-DCRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven (biopsy or cytology) NSCLC (SCC, Adenocarcinoma, Large Cell)&#xD;
&#xD;
          -  TNM clinical non-operable stage I/II and non-resectable stage IIIa/b without pleural&#xD;
             effusion&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No other malignancy, except non-melanomatous skin cancer, within 5 years prior to&#xD;
             participation in this study; the disease-free interval from any prior carcinoma must&#xD;
             be continuous&#xD;
&#xD;
          -  Patient suitable for radical 3-DCRT&#xD;
&#xD;
          -  ECOG-Performance status â‰¤ 2 / KPS &gt; or equal to 60&#xD;
&#xD;
          -  Weight loss &lt;10% within the 3 months prior to diagnosis&#xD;
&#xD;
          -  No prior radiotherapy to the thorax&#xD;
&#xD;
          -  Patient is suitable for lung-board immobilisation&#xD;
&#xD;
          -  No chemotherapy received prior to planning PET-CT scan&#xD;
&#xD;
          -  Age 18 and over&#xD;
&#xD;
          -  Provision of written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of any other significant clinical disorder or laboratory finding that makes&#xD;
             it undesirable for the patient to participate in the trial or if it is felt by the&#xD;
             research / medical team that the patient may not be able to comply with the protocol.&#xD;
&#xD;
          -  FEV1 &lt; 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Thirion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Luke's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Luke's Radiation Oncology Network</name>
      <address>
        <city>Dublin</city>
        <zip>6</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>malignant pleural effusion</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IA non-small cell lung cancer</keyword>
  <keyword>stage IB non-small cell lung cancer</keyword>
  <keyword>stage IIA non-small cell lung cancer</keyword>
  <keyword>stage IIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

